Collecting data on patients with plasmablastic lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational, multicenter, international study aims to gather comprehensive data on clinical and pathological characteristics, treatment regimens, outcomes, and prognostic factors in patients diagnosed with plasmablastic lymphoma (PBL). The study will retrospectively analyze medical records and histopathological samples from patients diagnosed between January 1, 2000, and December 31, 2022. A centralized review of pathological samples will be conducted to ensure accurate diagnosis and to establish a recommended immunohistochemical diagnostic panel for PBL. Additionally, exploratory analyses will be performed to enhance the understanding of PBL.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of plasmablastic lymphoma (PBL) between Jan 1st 2000, and Dec 31st 2022
* Histologically confirmed plasmablastic lymphoma (PBL) diagnosis according to local pathological report
* Age \> 18 years old
* Availability of complete medical records
* Availability of histopathological material requested by the study

Exclusion Criteria:

* Any other histology than PBL
* Lack of complete medical records
* Lack of histopathological material requested by the study

Where it's running

• IRCCS Centro di Riferimento Oncologico di Aviano, Divisione di Oncologia e dei Tumori immuno-correlati
  Aviano, Pn, Italy Recruiting
• Ospedale C.e G. Mazzoni, U.O.C. di Ematologia
  Ascoli Piceno, Italy Recruiting
• A.O. S. Croce e Carle, S.C. di Ematologia e Trapianto di Midollo Osseo
  Cuneo, Italy Recruiting
• Azienda Ospedaliera Universitaria Careggi, Unità funzionale di Ematologia
  Florence, Italy Recruiting
• ASST -Fatebenefratelli - Polo Luigi Sacco Oncologia
  Milan, Italy Recruiting
• ASST Grande Ospedale Metropolitano Niguarda, SC Ematologia
  Milan, Italy Recruiting

Study contacts

• Principal investigator: Alessia Castellino, MD — UO Ematologia, AO Santa Croce e Carle, Cuneo - Italy
• Study coordinator: Uffici Studi FIL
• Email: startup@filinf.it
• Phone: +390131033153

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Glofitamab with R-CHOP for Newly Diagnosed HIV-Related Large B-Cell Lymphoma

  This phase 1 study tests glofitamab plus R-CHOP chemoimmunotherapy in adults newly diagnosed with HIV-related large B-cell lymphoma to see if the regimen is safe and tolerable.

  Recruiting Phase 1 National Cancer Institute (NCI) · Rockville, Maryland · NCT07649304

• Elranatamab consolidation for newly diagnosed plasmablastic lymphoma

  This study tests whether giving Elranatamab after initial chemotherapy can help patients with plasmablastic lymphoma, with or without HIV, stay in remission.

  Recruiting Phase 1 University of Illinois Chicago · Chicago, Illinois · NCT07647432

• Collecting blood and tissue samples for HIV/AIDS-related cancer research

  This study is collecting blood and tissue samples from people living with HIV and related cancers to help researchers learn more about how HIV affects cancer development.

  Recruiting at 8 sites AIDS Malignancy Consortium · La Jolla, California and 7 other locations · NCT05663502

• Evaluating SGR-1505 for treating mature B-cell neoplasms

  This study is testing a new oral medication called SGR-1505 to see if it is safe and effective for people with certain types of B-cell lymphomas that have not responded to other treatments.

  Recruiting at 36 sites Phase 1 Schrödinger, Inc. · Gilbert, Arizona and 35 other locations · NCT05544019

• Combining Pomalidomide with Chemotherapy for HIV-Related Lymphomas

  This study is testing if adding a drug called pomalidomide to chemotherapy can help adults with HIV-related lymphomas feel better and improve their treatment outcomes.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05389423

• Evaluating a treatment combining Daratumumab, Bortezomib, and Dexamethasone for Plasmablastic Lymphoma

  This study is testing a new combination treatment of Daratumumab, Bortezomib, and Dexamethasone to see if it helps people with relapsed or hard-to-treat Plasmablastic Lymphoma.

  Recruiting at 14 sites Phase 2 Fondazione Italiana Linfomi - ETS · Ancona, Ancona and 17 other locations · NCT04915248

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.